|View printer-friendly version|
Board of Directors Increases Stock Repurchase Authorization by an
“Dr. Thompson’s experience overseeing oncology and immunology research,
and particularly his focus on translational medicine, will enhance the
expertise of Charles River’s Board,” said
Prior to joining
“I am pleased to join Charles River’s Board and to work with this outstanding team. I look forward to contributing to the future success and growth of this recognized global leader,” said Dr. Thompson.
Creates New Board Committee
In conjunction with Dr. Thompson’s election, the Charles River Board of
Directors also established a new Science and Technology Committee. This
Committee will focus on identifying significant emerging trends in
science and technology as well as consider the potential impact of these
trends on the Company. It will also be responsible for periodically
reviewing and advising the Board on the Company’s strategic direction
and investment in research and development activities. In addition to
Dr. Thompson, who will serve as the chairman, the Committee includes
current directors Mr.
Increases Stock Repurchase Authorization
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as "anticipate,"
"believe," "expect," "will," "may," "estimate," "plan," "outlook," and
"project" and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
Forward looking statements include statements in this press release
regarding future demand for drug discovery and development products and
services including the outsourcing of these services; the specific
contributions of members of Charles River's Board of Directors; and
expectations regarding market and industry conditions. Forward-looking
statements are based on Charles River's current expectations and
beliefs, and involve a number of risks and uncertainties that are
difficult to predict and that could cause actual results to differ
materially from those stated or implied by the forward-looking
statements, including the timing and magnitude of our share repurchases.
A further description of these risks, uncertainties, and other matters
can be found in the Risk Factors detailed in Charles River's Annual
Report on Form 10-K as filed on
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Executive Director, Public Relations